Hypercoagulability in β-thalassemia: A status quo

Expert Review of Hematology

Volumn 5, Issue 5, 2012, Pages 505-512

  Cappellini, Maria Domenica ^a   Poggiali, Erika ^a   Taher, Ali T ^b   Musallam, Khaled M ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

coagulopathy; hypercoagulability; thalassemia intermedia; thalassemia major; thrombosis

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ACETYLSALICYLIC ACID; HYDROXYUREA;

BETA THALASSEMIA; ENDOTHELIAL DYSFUNCTION; HEMOLYSIS; HUMAN; HYPERCOAGULABILITY; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SPLENECTOMY; THROMBOCYTE ACTIVATION; THROMBOEMBOLISM;

BETA-THALASSEMIA; HUMANS; PLATELET AGGREGATION; REACTIVE OXYGEN SPECIES; RISK FACTORS; THROMBOPHILIA;

EID: 84869151495     PISSN: 17474086     EISSN: 17474094     Source Type: Journal    
DOI: 10.1586/ehm.12.42     Document Type: Review

References (57)

1. Weatherall DJ, Clegg JB. The Thalassaemia Syndromes (4th Edition). Blackwell Science, Oxford, UK (2001).
2. Rund D, Rachmilewitz E. Beta-thalassemia. N. Engl. J. Med. 353(11), 1135-1146 (2005).
3. Cao A, Galanello R. Beta-thalassemia. Genet. Med. 12(2), 61-76 (2010).
4. Taher AT, Musallam KM, Cappellini MD, Weatherall DJ. Optimal management of b thalassaemia intermedia. Br. J. Haematol. 152(5), 512-523 (2011).
5. Taher A, Isma'eel H, Cappellini MD. Thalassemia intermedia: revisited. Blood Cells Mol. Dis. 37(1), 12-20 (2006).
6. Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood 99(1), 36-43 (2002).
7. Cappellini MD, Motta I, Musallam KM, Taher AT. Redefining thalassemia as a hypercoagulable state. Ann. NY Acad. Sci. 1202, 231-236 (2010).
8. Eldor A, Durst R, Hy-Am E et al. A chronic hypercoagulable state in patients with beta-thalassaemia major is already present in childhood. Br. J. Haematol. 107(4), 739-746 (1999).
9. Musallam KM, Taher AT Thrombosis in thalassemia: why are we so concerned? Hemoglobin 35(5-6), 503-510 (2011).
10. Ataga KI, Cappellini MD, Rachmilewitz EA. Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. Br. J. Haematol. 139(1), 3-13 (2007).
11. Winichagoon P, Fucharoen S, Wasi P. Increased circulating platelet aggregates in thalassaemia. Southeast Asian J. Trop. Med. Public Health 12(4), 556-560 (1981).
12. Del Principe D, Menichelli A, Di Giulio S, De Matteis W, Cianciulli P, Papa G. PADGEM/GMP-140 expression on platelet membranes from homozygous beta thalassaemic patients. Br. J. Haematol. 84(1), 111-117 (1993).
13. Ruf A, Pick M, Deutsch V et al. In vivo platelet activation correlates with red cell anionic phospholipid exposure in patients with beta-thalassaemia major. Br. J. Haematol. 98(1), 51-56 (1997).
14. Eldor A, Lellouche F, Goldfarb A, Rachmilewitz EA, Maclouf J. In vivo platelet activation in beta-thalassemia major reflected by increased plateletthromboxane urinary metabolites. Blood 77(8), 1749-1753 (1991).
15. Atichartakarn V, Angchaisuksiri P, Aryurachai K, Chuncharunee S, Thakkinstian A. In vivo platelet activation and hyperaggregation in hemoglobin E/beta-thalassemia: A consequence of splenectomy. Int. J. Hematol. 77(3), 299-303 (2003).
16. Cappellini MD, Grespi E, Cassinerio E, Bignamini D, Fiorelli G. Coagulation and splenectomy: An overview. Ann. NY Acad. Sci. 1054, 317-324 (2005).
17. Eldor A, Krausz Y, Atlan H et al. Platelet survival in patients with beta-thalassemia. Am. J. Hematol. 32(2), 94-99 (1989).
18. Goldschmidt N, Spectre G, Brill A et al. Increased platelet adhesion under flow conditions is induced by both thalassemic platelets and red blood cells. Thromb. Haemost. 100(5), 864-870 (2008).
19. Shinar E, Rachmilewitz EA, Lux SE. Differing erythrocyte membrane skeletal protein defects in alpha and beta thalassemia. J. Clin. Invest. 83(2), 404-410 (1989).
20. Hershko C, Graham G, Bates GW, Rachmilewitz EA. Non-specific serum iron in thalassaemia: An abnormal serum iron fraction of potential toxicity. Br. J. Haematol. 40(2), 255-263 (1978).
21. Tavazzi D, Duca L, Graziadei G, Comino A, Fiorelli G, Cappellini MD. Membrane-bound iron contributes to oxidative damage of beta-thalassaemia intermedia erythrocytes. Br. J. Haematol. 112(1), 48-50 (2001).
22. Borenstain-Ben Yashar V, Barenholz Y, Hy-Am E, Rachmilewitz EA, Eldor A. Phosphatidylserine in the outer leaflet of red blood cells from beta-thalassemia patients may explain the chronic hypercoagulable state and thrombotic episodes. Am. J. Hematol. 44(1), 63-65 (1993).
23. Helley D, Eldor A, Girot R, Ducrocq R, Guillin MC, Bezeaud A. Increased procoagulant activity of red blood cells from patients with homozygous sickle cell disease and beta-thalassemia. Thromb. Haemost. 76(3), 322-327 (1996).
24. Cappellini MD, Robbiolo L, Bottasso BM, Coppola R, Fiorelli G, Mannucci AP. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br. J. Haematol. 111(2), 467-473 (2000).
25. Chen S, Eldor A, Barshtein G et al. Enhanced aggregability of red blood cells of beta-thalassemia major patients. Am. J. Physiol. 270(6 Pt 2), H1951-H1956 (1996).
26. Butthep P, Bunyaratvej A, Funahara Y et al. Alterations in vascular endothelial cell-related plasma proteins in thalassaemic patients and their correlation with clinical symptoms. Thromb. Haemost. 74(4), 1045-1049 (1995).
27. Hovav T, Goldfarb A, Artmann G, Yedgar S, Barshtein G. Enhanced adherence of beta-thalassaemic erythrocytes to endothelial cells. Br. J. Haematol. 106(1), 178-181 (1999).
28. Butthep P, Rummavas S, Wisedpanichkij R, Jindadamrongwech S, Fucharoen S, Bunyaratvej A. Increased circulating activated endothelial cells, vascular endothelial growth factor, and tumor necrosis factor in thalassemia. Am. J. Hematol. 70(2), 100-106 (2002).
29. Carlos TM, Harlan JM. Leukocyteendothelial adhesion molecules. Blood 84(7), 2068-2101 (1994).
30. Habib A, Kunzelmann C, Shamseddeen W, Zobairi F, Freyssinet JM, Taher A. Elevated levels of circulating procoagulant microparticles in patients with beta-thalassemia intermedia. Haematologica 93(6), 941-942 (2008).
31. Iolascon A, Giordano P, Storelli S et al. Thrombophilia in thalassemia major patients: Analysis of genetic predisposing factors. Haematologica 86(10), 1112-1113 (2001).
32. Zalloua PA, Shbaklo H, Mourad YA, Koussa S, Taher A. Incidence of thromboembolic events in Lebanese thalassemia intermedia patients. Thromb. Haemost. 89(4), 767-768 (2003).
33. Giordano P, Galli M, Del Vecchio GC et al. Lupus anticoagulant, anticardiolipin antibodies and hepatitis C virus infection in thalassaemia. Br. J. Haematol. 102(4), 903-906 (1998).
34. Taher AT, Otrock ZK, Uthman I, Cappellini MD. Thalassemia and hypercoagulability. Blood Rev. 22(5), 283-292 (2008).
35. Musallam KM, Cappellini MD, Wood JC et al. Elevated liver iron concentration is a marker of increased morbidity in patients with b thalassemia intermedia. Haematologica 96(11), 1605-1612 (2011).
36. Zurlo MG, De Stefano P, Borgna-Pignatti C et al. Survival and causes of death in thalassaemia major. Lancet 2(8653), 27-30 (1989). 37 Borgna-Pignatti C, Carnelli V, Caruso V et al. Thromboembolic events in beta thalassemia major: An Italian multicenter study. Acta Haematol. 99(2), 76-79 (1998).
37. Borgna-Pignatti C, Rugolotto S, De Stefano P et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 89(10), 1187-1193 (2004).
38. Taher A, Isma'eel H, Mehio G et al. Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb. Haemost. 96(4), 488-491 (2006).
39. Taher AT, Musallam KM, Karimi M et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: The OPTIMAL CARE study. Blood 115(10), 1886-1892 (2010).
40. Taher AT, Musallam KM, El-Beshlawy A et al. Age-related complications in treatment-naïve patients with thalassaemia intermedia. Br. J. Haematol. 150(4), 486-489 (2010).
41. Taher AT, Musallam KM, Karimi M et al. Splenectomy and thrombosis: The case of thalassemia intermedia. J. Thromb. Haemost. 8(10), 2152-2158 (2010).
42. Logothetis J, Constantoulakis M, Economidou J et al. Thalassemia major (homozygous beta-thalassemia). A survey of 138 cases with emphasis on neurologic and muscular aspects. Neurology 22(3), 294-304 (1972).
43. Karimi M, Khanlari M, Khanlari M, Rachmilewitz EA. Cerebrovascular accident in beta-thalassemia major (beta-TM) and beta-thalassemia intermedia (beta-TI). Am. J. Hematol. 83(1), 77-79 (2008).
44. Vassilopoulou S, Anagnostou E, Paraskevas G, Spengos K. Etiology and treatment of ischaemic stroke in patients with b-thalassemia major. Eur. J. Neurol. 18(12), 1426-1428 (2011).
45. Haghpanah S, Karimi M. Cerebral thrombosis in patients with b-thalassemia: A systematic review. Blood Coagul. Fibrinolysis 23(3), 212-217 (2012).
46. Manfrè L, Giarratano E, Maggio A, Banco A, Vaccaro G, Lagalla R. MR imaging of the brain: findings in asymptomatic patients with thalassemia intermedia and sickle cell-thalassemia disease. AJR. Am. J. Roentgenol. 173(6), 1477-1480 (1999).
47. Taher AT, Musallam KM, Nasreddine W, Hourani R, Inati A, Beydoun A. Asymptomatic brain magnetic resonance imaging abnormalities in splenectomized adults with thalassemia intermedia. J. Thromb. Haemost. 8(1), 54-59 (2010).
48. Musallam KM, Beydoun A, Hourani R et al. Brain magnetic resonance angiography in splenectomized adults with b-thalassemia intermedia. Eur. J. Haematol. 87(6), 539-546 (2011).
49. Ashjazadeh N, Emami S, Petramfar P, Yaghoubi E, Karimi M. Intracranial blood flow velocity in patients with b-thalassemia intermedia using transcranial Doppler sonography: A case-control study. Anemia 2012, 798296 (2012).
50. Karimi M, Bagheri H, Rastgu F, Rachmilewitz EA. Magnetic resonance imaging to determine the incidence of brain ischaemia in patients with beta-thalassaemia intermedia. Thromb. Haemost. 103(5), 989-993 (2010).
51. Teli A, Economou M, Rudolf J et al. Subclinical central nervous system involvement and thrombophilic status in young thalassemia intermedia patients of Greek origin. Blood Coagul. Fibrinolysis 23(3), 195-202 (2012).
52. Akhlaghpoor S, Ghahari A, Morteza A, Khalilzadeh O, Shakourirad A, Alinaghizadeh MR. Quantitative T2 magnetic resonance imaging for evaluation of iron deposition in the brain of b-thalassemia patients. Clin. Neuroradiol. 22(3), 211-217 (2012).
53. Musallam KM, Nasreddine W, Beydoun A et al. Brain positron emission tomography in splenectomized adults with b-thalassemia intermedia: uncovering yet another covert abnormality. Ann. Hematol. 91(2), 235-241 (2012).
54. Armstrong FD. Thalassemia and learning: Neurocognitive functioning in children. Ann. NY Acad. Sci. 1054, 283-289 (2005).
55. Crary SE, Buchanan GR. Vascular complications after splenectomy for hematologic disorders. Blood 114(14), 2861-2868 (2009).
56. Karimi M, Darzi H, Yavarian M. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. J. Pediatr. Hematol. Oncol. 27(7), 380-385 (2005).
57. Tripodi A, Cappellini MD, Chantarangkul V et al. Hypercoagulability in splenectomized thalassemic patients detected by whole-blood thromboelastometry, but not by thrombin generation in platelet-poor plasma. Haematologica 94(11), 1520-1527 (2009). (Pubitemid 20357658)